Takeda’s Alunbrig To Battle Entrenched EU Competitors In First-Line ALK-Positive NSCLC
Bayer/Orion’s Nubeqa Also Cleared For Prostate Cancer
EU Approvals: Takeda advances its targeted ALK-positive NSCLC tyrosine kinase inhibitor into early lines of therapy, while Bayer and Finland’s Orion gain clearance for their androgen receptor inhibitor for prostate cancer.
You may also be interested in...
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.
The latest drug development news and highlights from our US FDA Performance Tracker.